Application of combined therapy with molecular-targeted drugs and immune checkpoint inhibitors and other combined therapies in hepatocellular carcinoma
DOI:10.3969/j.issn.1001-5256.2021.04.043
- VernacularTitle:分子靶向药物与免疫抑制剂联合治疗及其他联合治疗在肝细胞癌中的应用
- Author:
Jingzhong OUYANG
1
;
Yanzhao ZHOU
;
Ruili ZHU
;
Zhengzheng WANG
;
Xun CHEN
;
Jinxue ZHOU
;
Qingjun LI
Author Information
1. Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou 450000, China
- Publication Type:Research Article
- Keywords:
Carcinoma, Hepatocellular;
Molecular Targeted Therapy;
Immunosuppression;
Radiotherapy;
Surgery;
Drug Therapy, Combination
- From:
Journal of Clinical Hepatology
2021;37(4):925-930
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors, and its features of insidious onset, rapid development, and high recurrence bring great challenges to the long-term survival of HCC patients. Molecular-targeted drugs and immune checkpoint inhibitors have become the research hotspots in the treatment of HCC, and a large number of clinical trials have found that combined therapy has achieved a good clinical effect. This article mainly introduces the application of combined therapy with molecular-targeted drugs and immune checkpoint inhibitors and other combined therapies in HCC and points out that combined therapy related to systemic therapy or local therapy has become the latest research hotspot in HCC treatment.
